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ABSTRACT: High-performance liquid chromatography was used
in combination with infrared ion spectroscopy for the
identiﬁcation of positional isomers of hydroxy-atorvastatins, the
primary metabolites of the drug atorvastatin. The results
demonstrate the direct applicability of infrared ion spectroscopy
in the ﬁeld of drug metabolism and, more generally, its promising
role in state-of-the-art analytical laboratories for the identiﬁcation
of small molecules buried in complex mixtures. In combination
with chromatographic separation, infrared spectroscopy of mass-
selected ions provides a promising new route for the identiﬁcation
of the molecular structures of unknown m/z peaks in a mass
spectrum. We demonstrate that currently existing experimental
protocols allow the measurement of an IR spectrum from less than 10 ng of sample obtained in a collected HPLC fraction.
The study of drug metabolism, i.e., the degradation of acompound in the body, is an important component of the
drug development process. Predominantly, diﬀerent mass
spectrometric (MS) techniques are used in combination with
liquid chromatography (LC) for the separation and identi-
ﬁcation of drug metabolites. However, the localization of the
exact site of a metabolic biotransformation by mass
spectrometric analysis alone is often challenging or impossible
since regioisomeric metabolites are frequently indistinguishable
on the basis of their MS/MS product ion data, e.g., positional
isomers with a site of metabolic modiﬁcation on an aromatic
ring.1 Therefore, nuclear magnetic resonance (NMR) spectros-
copy is often needed for the complete identiﬁcation of a
metabolite structure. However, this technique requires large
amounts (typically >5−100 μg) of sample in high purity.2 Since
the metabolite can often only be extracted from biological (in
vitro or in vivo) matrixes, this involves a time-consuming and
complex puriﬁcation process. The latter is currently the main
bottleneck for more regular use of NMR for the identiﬁcation
of drug metabolites.1−3
The combination of mass spectrometry and infrared
spectroscopy, known as infrared ion spectroscopy (IR-IS), is
well established as a powerful tool for the elucidation of
molecular structures and conformations of gas phase ions.4−7
Using the combination of state-of-the-art commercial ion trap
mass spectrometry platforms8−10 with intense and tunable
infrared lasers, such as user facility-based free electron lasers
(FELs)11,12 and table top optical parametric oscillators,13−15 an
infrared spectrum can be generated for ions at any m/z peak in
a mass spectrum.
IR-IS has the potential to become a very valuable alternative
for structural elucidation by NMR in many cases.16 Since the
technique is based on detection by mass spectrometry, with its
well-known selectivity and sensitivity, it can provide full
structure information from one simple LC/MS or MS analysis
and overcomes the tedious metabolite puriﬁcation needed for
NMR. Since less material is needed for the analysis, also less in
vitro and/or in vivo sample needs to be produced, resulting in
the use of fewer animals. Also, unstable metabolites that are
hard or impossible to extract and purify can be measured using
IR ion spectroscopy.
Recent examples of modiﬁed commercial ion trap mass
spectrometers used for IR-IS measurements enable sensitivity
down to the low nanomolar regime and require ∼50 μL of
sample solution per IR spectrum.8 This sensitivity thus enables
the measurement of IR spectra of ions that are components of
collected HPLC fractions by direct infusion electrospray
ionization (ESI). Here, we demonstrate the combination of
HPLC and IR-IS and apply it for the identiﬁcation of molecular
structures in the ﬁeld of drug metabolism. Atorvastatin is an
extensively studied HMG-CoA reductase inhibitor used as a
lipid-lowering drug.17,18 Its primary metabolism pathway is
through cytochrome P450 3A4 hydroxylation, giving active
ortho- and para-hydroxylated metabolites that in fact account
for a signiﬁcant portion of the HMG-CoA reductase activity.19
Incubation of atorvastatin in human liver microsomes showed
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two major metabolites that were separated and collected by
HPLC and identiﬁed as the ortho- and para-hydroxy
metabolites on the basis of their IR spectra measured using
IR-IS.
■ METHODS
Chemicals and Materials. Atorvastatin was purchased
from Sequoia Research Products (Pangbourne, United King-
dom). The metabolites, o- and p-hydroxylated atorvastatin,
were obtained from TLC PharmaChem (Ontario, Canada).
Methanol and acetonitrile were supplied by Merck (Darmstadt,
Germany); formic acid (0.1% in water) was provided by
Biosolve (Valkenswaard, The Netherlands), and the dimethyl
sulfoxide (DMSO) used during sample preparation was from
Merck (Darmstadt, Germany). All LC solvents were HPLC
grade.
Sample Preparation. Atorvastatin was incubated at 10 μM
for 120 min in human liver microsomes with a ﬁnal protein
concentration of 1 mg/mL. The cell incubations (500 μL) were
extracted with DMSO (500 μL), vortexed, sonicated, and
centrifuged for 10 min at 16 060g. A 100 μL aliquot of the
resulting supernatant was injected for analysis.
LC Fractionation. An Acquity i-class UPLC system
(Waters, Manchester, UK), equipped with an Acquity FTN
sample manager and an Acquity PDA detector, was coupled to
a Gilson PrepFC sample collector (Middleton, USA). The
separation was performed on a 150 × 3 mm Uptisphere
Strategy C18-2 column (Interchim, Montluco̧n, France) packed
with 2.2 μm particles and kept at a temperature of 60 °C.
Elution started with a linear gradient at a ﬂow rate of 0.8 mL/
min from 95% solvent A (0.1% formic acid in water) and 5%
solvent B (acetonitrile/methanol 80/20; v/v%) to 30% solvent
A and 70% solvent B over 10 min, increased further to 100% B
in 0.1 min, and was kept at 100% B for 2 min. The column
eluent ﬁrst passed through the PDA detector and was
subsequently fractionated every 6 s into a 96-well plate.
Afterward, the fractions (80 μL) corresponding to the peaks of
interest were pooled. The collections corresponded to 57, 106,
and 120 ng of peaks A, B, and C, respectively (Figure 1).
Infrared Ion Spectroscopy. IR-IS measurements were
performed in a modiﬁed quadrupole ion trap mass
spectrometer (Bruker, AmaZon Speed ETD) coupled to the
beamline of the FELIX IR-FEL. Details of the hardware
modiﬁcations and of software operation have been previously
reported.8,20 Collected HPLC fractions were directly electro-
sprayed (+ESI) to produce IR/mass spectra. All reference
measurements were generated by +ESI from solutions of 10−7
M in 50:50 MeOH/H2O. The FELIX free electron laser
generates infrared radiation as 5−10 μs macropulses at a 10 Hz
repetition rate having ∼40 mJ pulse energy and a bandwidth of
∼0.4% of the center frequency.
In contrast to classical absorption IR spectroscopy, IR-IS is a
form of action spectroscopy in which infrared absorption is
monitored by observation of the photodissociation it induces.
IR photons are absorbed when they are resonant with a
vibration of the trapped ions, resulting in an increase in internal
energy. Intramolecular vibrational redistribution of the
absorbed energy causes ions to dissociate once they reach the
limit of the dissociation channel having the lowest threshold.
Typically, after a single IR macropulse, dissociation occurs.
Relating the parent and fragment ion intensities (IR yield =
ΣI(fragment ions)/ΣI(parent + fragment ions)) as the IR
frequency is tuned generates an infrared vibrational spectrum.
The yield at each IR point is typically obtained from four to
eight averaged mass spectra, and the frequency is calibrated
online throughout the measurements using a grating
spectrometer.
■ RESULTS AND DISCUSSION
As detailed above, atorvastatin (10 μM) was incubated in
human liver microsomes for 120 min to generate the relevant
metabolites which were separated by HPLC and the relevant
fractions were collected. Demonstrated in Figure 1, the two
isobaric metabolites, while separable by HPLC (panel I), are
unidentiﬁable on the basis of their MS/MS product ion spectra
showing identical product ions with identical relative
abundances (panel II). The structures of atorvastatin and the
two hydroxylated metabolites are illustrated in Figure 2. Using
instead the HPLC/IR-IS approach, we are able to ﬁrst separate
the two hydroxylated metabolites using HPLC and then
identify them on the basis of their readily distinguishable IR
spectra. Using direct infusion +ESI, the ions were generated
from the collected HPLC fractions. These results are illustrated
in panels I−III of Figure 2. Note that these metabolites are
distinguishable by their vibrational signatures in both the
1000−1900 cm−1 spectral region (measured using the FELIX
IR FEL) and the 3200−3700 cm−1 spectral region (measured
using a table top IR optical parametric oscillator laser source,
LaserVision, USA). Using identical experimental (MS and IR
Figure 1. Hydroxy-atorvastatins are separable by HPLC (panel I) but
indistinguishable on the basis of their MS/MS spectra (panel II).
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laser) conditions, distinction can be made on both the basis of
line positions (for example, peak splitting in the regions of
∼1250 and 3650 cm−1) and diﬀerences in IR fragment yields
(intensities) since both properties of the IR spectra are highly
reproducible.
From the HPLC experiments, fractions were collected
containing the relevant metabolites at ∼300 nM and IR
measurements were obtained in duplicate in both spectral
regions from a single collected fraction. Note that these
amounts of sample are directly compatible with the standard
operating protocols of the experiment8 since the measurement
of one IR spectrum typically takes 10−20 min using ESI ﬂow
rates of ∼2 μL/min and concentrations ranging from nM to
μM (in this case, corresponding to less than 10 ng of sample
consumption per IR spectrum). Such experimental conditions
compare very favorably against the alternative use of NMR
spectroscopy for such an identiﬁcation, maintaining the
sensitivity and selectivity inherent to mass spectrometry while
providing orthogonal identiﬁcation on the basis of retention
time, mass-to-charge, and IR spectral ﬁngerprint.
Comparison of the IR-IS spectra from the HPLC fractions to
IR-IS spectra of the pure reference compounds recorded under
the same conditions (see black traces in panels I and II of
Figure 2) shows that identical IR spectra are generated
independently of the purity and concentration of the sample
due to the selectivity of the MS. A particularly interesting
perspective of the current approach is to rely on quantum−
chemically calculated IR spectra in place of reference IR
measurements, unlocking the potential of reference-free
identiﬁcation of unknowns in cases where model compounds
are not commercially or synthetically available.21−23 This is
hardly possible from MS/MS or LC data as CID fragmentation
Figure 2. Panels I and II present IR spectra (colored traces) generated for ions at m/z 575 from LC fractions A and B and the identiﬁcation of
isobaric drug metabolites based on IR spectral match with reference compounds (black traces). Panel III highlights the diﬀerence in IR spectra of the
two isomeric metabolites. Panel IV contains the IR spectrum measured for unmetabolized atorvastatin (peak C in LC chromatogram presented in
Figure 1).
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propensities and retention times are hard or even impossible to
reliably compute. On the other hand, IR spectral predictions
from quantum−chemical calculations are rapidly approaching
experimental accuracy. Additionally, information on the
functional groups contained in an unknown molecule is
contained in its IR spectrum. For example, the IR features at
approximately 3650 cm−1 in panels I and II of Figure 2 are a
strong indication of OH functionality. Identiﬁcation of speciﬁc
functional groups in a molecule can be, for example, useful for
narrowing down a list of isobaric compounds in a database
search. In the case of coeluting isobaric compounds, a
composite IR spectrum of all species is obtained. However, if
speciﬁc spectral contributions from each compound are
suﬃciently distinct (in terms of frequency), deconvolution is
often possible. Moreover, for compounds showing diﬀerent
fragmentation, unique IR spectra can be generated for each
isobaric precursor by monitoring speciﬁc fragment ions
Currently, only a few laboratories worldwide possess the MS
and IR laser infrastructure to conduct routine IR-IS experi-
ments. This is mainly a result of the limited availability of FELs
and the low output power and limited tuning ranges of OPOs.
However, several FEL facilities (including FELIX) are open to
external researchers. Moreover, with the ongoing introduction
of new mid-IR laser sources (such as external cavity tunable
quantum cascade lasers), implementation of aﬀordable bench-
top IR-IS techniques in state-of-the-art analytical laboratories
for small molecule identiﬁcation is quickly becoming a reality.
This is especially exciting for online screening approaches in
HPLC/MS analyses using a limited IR frequency range.
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